Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
J Clin Oncol. 2024 Aug 9:JCO2400826. doi: 10.1200/JCO.24.00826. Online ahead of print. ABSTRACT PURPOSE: Revumenib, an oral, small molecule inhibitor of the menin-lysine methyltransferase 2A …